CN105017124A - 一种合成黄皮酰胺的新方法 - Google Patents
一种合成黄皮酰胺的新方法 Download PDFInfo
- Publication number
- CN105017124A CN105017124A CN201510403792.1A CN201510403792A CN105017124A CN 105017124 A CN105017124 A CN 105017124A CN 201510403792 A CN201510403792 A CN 201510403792A CN 105017124 A CN105017124 A CN 105017124A
- Authority
- CN
- China
- Prior art keywords
- pyrrolidone
- mixture
- reaction
- silica gel
- gel column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- WGYGSZOQGYRGIP-MWDXBVQZSA-N (3r,4s,5s)-3-hydroxy-5-[(r)-hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one Chemical compound C1([C@@H](O)[C@H]2N(C([C@H](O)[C@H]2C=2C=CC=CC=2)=O)C)=CC=CC=C1 WGYGSZOQGYRGIP-MWDXBVQZSA-N 0.000 title claims 3
- VRSSZILNAITUII-UHFFFAOYSA-N Clausenamide Natural products OC1C(=O)N(C)C=CC2=CC=CC=C2C1C1=CC=CC=C1 VRSSZILNAITUII-UHFFFAOYSA-N 0.000 title claims 3
- WGYGSZOQGYRGIP-UHFFFAOYSA-N neoclausenamide Natural products C=1C=CC=CC=1C1C(O)C(=O)N(C)C1C(O)C1=CC=CC=C1 WGYGSZOQGYRGIP-UHFFFAOYSA-N 0.000 title claims 3
- 230000002194 synthesizing effect Effects 0.000 title abstract description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- 239000012044 organic layer Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000010898 silica gel chromatography Methods 0.000 claims description 12
- 238000004809 thin layer chromatography Methods 0.000 claims description 12
- -1 alkynes nitrile Chemical class 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- 239000011541 reaction mixture Substances 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- LYUARYSAVQUGLK-UHFFFAOYSA-N lithium;triethylborane Chemical compound [Li].CCB(CC)CC LYUARYSAVQUGLK-UHFFFAOYSA-N 0.000 claims description 3
- ONDXXAPHPJPFKQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphoryl]-n-methylmethanamine;oxolane Chemical compound C1CCOC1.CN(C)P(=O)(N(C)C)N(C)C ONDXXAPHPJPFKQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- PHQIAQCZFCLYKL-UHFFFAOYSA-N sulfuric acid;tungsten Chemical compound [W].OS(O)(=O)=O PHQIAQCZFCLYKL-UHFFFAOYSA-N 0.000 claims description 3
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000001308 synthesis method Methods 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 13
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- 239000002904 solvent Substances 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- 229960004526 piracetam Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 0 CC(C1C(CC2*C2)CCCC1)=C Chemical compound CC(C1C(CC2*C2)CCCC1)=C 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HALONVPKHYIEQU-UHFFFAOYSA-N 3-phenyloxirane-2-carboxylic acid Chemical compound OC(=O)C1OC1C1=CC=CC=C1 HALONVPKHYIEQU-UHFFFAOYSA-N 0.000 description 1
- BYMDZVGDXBSIHW-VOMCLLRMSA-N CN(C1)C2OC2C[C@H]1c1ccccc1 Chemical compound CN(C1)C2OC2C[C@H]1c1ccccc1 BYMDZVGDXBSIHW-VOMCLLRMSA-N 0.000 description 1
- 238000003476 Darzens condensation reaction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- DQDCGTUHSVXZIS-UHFFFAOYSA-N iodobenzene;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.IC1=CC=CC=C1 DQDCGTUHSVXZIS-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
Abstract
本发明公开了一种合成黄皮酰胺的新方法,它是以炔腈为原料,经过四步反应,合成黄皮酰胺。该方法原料廉价易得,合成方法简单,反应条件温和可控,原子经济性好,产率高。
Description
技术领域
本发明涉及黄皮酰胺药物,具体是一种合成黄皮酰胺的新方法。
背景技术
阿尔茨海默氏症(Alzheimer’s disease,AD)也称为老年痴呆,是一种由多源性因素引起的原发性大脑神经系统退行性疾病(Nature,1987,325,658-659)。据欧美国家的统计,60岁以上老年人6-12%发生痴呆,85岁以上的老人则有20-48%发生痴呆。据我国老年痴呆病大规模调查显示,我国老年痴呆症的发病率已接近欧美国家。目前全球约有超过2000万老年性痴呆患者,我国有约645万人患有该病,且每年仍以数十万新患者的速度迅猛递增。而随着社会人口的日益老年化,AD发病率正逐年升高。据预测,2030年全球患AD的人数将达到6000万,而我国就将有1200万(Nature,2012,488,38-39)。由于AD的致残率较高,对人类健康造成严重危害,已成为继心脏病,肿瘤,脑中风之后人类第4号杀手,对AD病人的医疗和照料还耗费了大量人力、物力和财力,老年痴呆已成为一个棘手的社会问题。因此,寻找治疗老年痴呆症的有效药物,已成为医药领域的研究热点之一。
黄皮酰胺含有抗老年痴呆药-脑复康(吡拉西坦,Piracetam)的功效结构,是从广西特色植物黄皮(芸香科黄皮属)叶的水浸膏中分离得到的有效成分之一,具有抗老年痴呆、抗氧化(如清除自由基)、护肝等重要的药理活性,黄皮酰胺类化合物被认为是最有希望成为新型抗老年痴呆和抗肝炎药物的化合物(Org.Biomol.Chem.,2009,7,2628-2634;Bioorg.Med.Chem.Lett.,2009,19,2112-2115)。其结构式为:
目前黄皮酰胺的全合成方法主要有两种,方法一是1988年由德国Bayer公司和中国医学科学院药物研究所合作完成,以肉桂酸酯为起始物,经10步合成黄皮酰胺,此方法步骤繁多,总产率较低(US 4731455)。方法二是1994年由中国医学科学院药物研究所报道的5步合成法,以苯甲醛和氯乙酸甲酯为原料在甲醇钠的催化下经Darzens缩合反应得β-苯基缩水甘油酸甲酯,再经酯胺交换、氧化、环合生成外消旋黄皮酰胺酮,通过分步重结晶分离得到光学纯黄皮酰胺酮,后经还原反应获得黄皮酰胺(药学学报,1994,29,502-505)。然而这两种合成方法中多个反应步骤需要使用强碱,反应条件比较苛刻,且反应的原子经济性差,因此获得一种简单、高效、原子经济性的黄皮酰胺的新全合成方法是亟待解决的问题。目前尚未见利用炔腈为原料合成黄皮酰胺的报道。
发明内容
本发明的目的是提供一种简单,高效,原子经济性好的黄皮酰胺的合成方法。
本发明以炔腈为原料,合成黄皮酰胺,其制备方法包括如下步骤:
(1)在封管中加入甲醇、炔腈1和钨硫酸,混合物在100℃下反应并用薄层色谱监测,反应完毕,冷却并用乙酸乙酯稀释混合物,过滤除去催化剂,有机层在减压下旋去溶剂,残留物经硅胶柱层析分离得到纯的炔酰胺2,其反应式为:
(2)将炔酰胺2溶于三氟乙醇中,溶液冷却至0℃,滴入二(三氟乙酸)碘苯三氟乙醇溶液,反应混合物在0℃下搅拌反应并用薄层色谱监测,反应完毕,加入碳酸钠水溶液,用二氯甲烷萃取三次,合并有机层,有机层用饱和氯化钠水溶液洗涤,再用无水硫酸钠干燥,旋去溶剂,得到3a/3b比例为1.6/1.4的混合物,混合物经硅胶柱层析分离得到纯的吡咯烷酮3b,其反应式为:
(3)将步骤(2)所得的吡咯烷酮3b在-15℃至-20℃,氮气保护下,将三乙基硼锂(LiBEt3H,1M)四氢呋喃溶液滴入吡咯烷酮3b四氢呋喃溶液中,反应混合物在0℃下搅拌1小时,用盐酸淬灭,乙酸乙酯萃取两次,有机层用无水硫酸镁干燥,旋去溶剂,残留物经硅胶柱层析分离得到纯的吡咯烷酮4b,其反应式为:
(4)将步骤(3)得到的吡咯烷酮4b在-70℃、氮气保护下,将二异丙基氨基锂(1.5N)四氢呋喃溶液滴入吡咯烷酮4b和六甲基磷酸三酰胺四氢呋喃溶液中,反应混合物在-60℃至-70℃下搅拌1小时,后加入亚磷酸三甲酯和通入氧气,用薄层色谱监测,反应完毕,用盐酸淬灭,乙酸乙酯萃取四次,有机层用饱和氯化钠水溶液洗涤,再用无水硫酸钠干燥,旋去溶剂,残留物经硅胶柱层析分离得到纯的黄皮酰胺,其反应式为:
本发明原料廉价易得,合成方法简单,反应条件温和可控,原子经济性好,产率高。
具体实施方式
下面结合实施例对本发明作进一步的阐述,但不是对本发明的限定。
实施例:
一种合成黄皮酰胺的新方法,其合成路线为:
其合成方法步骤如下:
(1)往封管中加入甲醇(10mmol)、4-炔腈1(5mmol)和钨硫酸(20wt%),混合物在100℃下反应并用薄层色谱(TLC)监测。一旦反应完毕,冷却并用乙酸乙酯稀释混合物,过滤除去催化剂,有机层在减压下旋去溶剂,残留物进行硅胶柱层析分离得到纯的4-炔酰胺2,产率85%;
所得4-炔酰胺2经检测,呈白色固体,熔点96-98℃;1H NMR(500Hz,CDCl3)δ2.52-2.89(m,5H),4.43(dd,J=7.9,7.1,1H),6.12(brs,1H),7.21-7.46(m,10H).13C NMR(125Hz,CDCl3)δ26.2,35.0,45.5,83.7,90.0,123.1,127.0,127.2,127.9,128.1,128.5,131.5,140.5,170.8.HRMScalculated for C18H17NO 263.1310,found 263.1321.
(2)将4-炔酰胺2(3.6mmol)溶于三氟乙醇中,溶液冷却至0℃,滴入6mL二(三氟乙酸)碘苯(PIFA,5.4mmol)三氟乙醇溶液,反应混合物在0℃下搅拌反应并用薄层色谱(TLC)监测。一旦反应完毕,加入5mL 10%碳酸钠水溶液,用10mL二氯甲烷萃取三次,合并有机层,有机层用饱和氯化钠水溶液洗涤,再用无水硫酸钠干燥,旋去溶剂,得到3a/3b比例为1.6/1.4的混合物,总产率70%,硅胶柱层析分离得到纯的吡咯烷酮3b;
所得吡咯烷酮3b经检测,呈白色固体,熔点116–117℃;1H NMR(500Hz,CDCl3)δ2.68–2.98(m,5H),4.02(q,J=8.3,1H),5.42(d,J=8.3,1H),6.92-7.10(m,5H),7.18-7.22(m,2H),7.25-7.60(m,3H).13C NMR(125Hz,CDCl3)δ29.2,36.0,42.3,67.5,126.3,126.5,127.2,127.8,133.7,135.0,135.2,175.0,196.2.HRMS calculated for C18H17NO2279.1259,found279.1232.
(3)将步骤(2)所得吡咯烷酮3b在-15℃至-20℃,氮气保护下,将2.4mL三乙基硼锂(LiBEt3H,1M)四氢呋喃溶液滴入吡咯烷酮3b(2mmol)四氢呋喃溶液中,反应混合物在0℃下搅拌1小时,用3mL盐酸(1N)淬灭,12mL乙酸乙酯萃取两次,有机层用无水硫酸镁干燥,旋去溶剂,残留物进行硅胶柱层析分离得到纯的吡咯烷酮4b,产率72%;
所得吡咯烷酮4b经检测,呈白色固体,熔点195-196℃;1H NMR(500MHz,DMSO-d6)δ2.0-2.65(m,2H);2.91(s,3H);3.80(dt,J=8.2Hz,1.3Hz,1H);4.24(dd,J=8.2Hz,1.5Hz,1H);4.65(dd,J=1.5Hz,3.5Hz,1H);5.32(d,J=3.5Hz,1H);6.70-7.25(m,10H).HRMScalculated for C18H19NO2281.1416,found 281.1445.
(4)将步骤(3)所得吡咯烷酮4b在-70℃,氮气保护下,将3mL二异丙基氨基锂(1.5N)四氢呋喃溶液滴入吡咯烷酮4b(1mmol)和六甲基磷酸三酰胺四氢呋喃溶液中(7mL),反应混合物在-60℃至-70℃下搅拌1小时,后加入0.1mL亚磷酸三甲酯和通入氧气,用薄层色谱(TLC)监测。一旦反应完毕,用10mL 0.5N盐酸淬灭,5mL乙酸乙酯萃取四次,有机层用饱和氯化钠水溶液洗涤,再用无水硫酸钠干燥,旋去溶剂,残留物进行硅胶柱层析分离得到纯的黄皮酰胺,产率61%。
所得黄皮酰胺产品经检测结果如下:产品呈白色固体,熔点234-235℃;1H NMR(500MHz,DMSO-d6)δ6.80-7.28(m,10H),5.71(d,J=4.5Hz,1H),5.58(d,J=5.7Hz,1H),5.02(t,J=3.4Hz,1H),3.81-3.94(m,2H),3.06(t,J=7.1,Hz,1H),2.92(s,3H).HRMS calculated for C18H19NO3297.1365,found 297.1312.
Claims (2)
1.一种合成黄皮酰胺的方法,其特征是:包括如下步骤:
(1)在封管中加入甲醇、炔腈1和钨硫酸,混合物在100℃下反应并用薄层色谱监测,反应完毕,冷却并用乙酸乙酯稀释混合物,过滤除去催化剂,有机层在减压下旋去溶剂,残留物经硅胶柱层析分离得到纯的炔酰胺2,其反应式为:
(2)将炔酰胺2溶于三氟乙醇中,溶液冷却至0℃,滴入二(三氟乙酸)碘苯三氟乙醇溶液,反应混合物在0℃下搅拌反应并用薄层色谱监测,反应完毕,加入碳酸钠水溶液,用二氯甲烷萃取三次,合并有机层,有机层用饱和氯化钠水溶液洗涤,再用无水硫酸钠干燥,旋去溶剂,得到3a/3b比例为1.6/1.4的混合物,混合物经硅胶柱层析分离得到纯的吡咯烷酮3b,其反应式为:
(3)将步骤(2)所得的吡咯烷酮3b在-15℃至-20℃,氮气保护下,将三乙基硼锂(LiBEt3H,1M)四氢呋喃溶液滴入吡咯烷酮3b四氢呋喃溶液中,反应混合物在0℃下搅拌1小时,用盐酸淬灭,乙酸乙酯萃取两次,有机层用无水硫酸镁干燥,旋去溶剂,残留物经硅胶柱层析分离得到纯的吡咯烷酮4b,其反应式为:
(4)将步骤(3)得到的吡咯烷酮4b在-70℃、氮气保护下,将二异丙基氨基锂(1.5N)四氢呋喃溶液滴入吡咯烷酮4b和六甲基磷酸三酰胺四氢呋喃溶液中,反应混合物在-60℃至-70℃下搅拌1小时,后加入亚磷酸三甲酯和通入氧气,用薄层色谱监测,反应完毕,用盐酸淬灭,乙酸乙酯萃取四次,有机层用饱和氯化钠水溶液洗涤,再用无水硫酸钠干燥,旋去溶剂,残留物经硅胶柱层析分离得到纯的黄皮酰胺,其反应式为:
2.根据权利要求1所述的方法,其特征是:合成路线为:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510403792.1A CN105017124A (zh) | 2015-07-10 | 2015-07-10 | 一种合成黄皮酰胺的新方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510403792.1A CN105017124A (zh) | 2015-07-10 | 2015-07-10 | 一种合成黄皮酰胺的新方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105017124A true CN105017124A (zh) | 2015-11-04 |
Family
ID=54407479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510403792.1A Pending CN105017124A (zh) | 2015-07-10 | 2015-07-10 | 一种合成黄皮酰胺的新方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105017124A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107056635A (zh) * | 2017-06-09 | 2017-08-18 | 广西师范大学 | 一种炔酰胺类化合物的合成方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN86107090A (zh) * | 1985-10-18 | 1987-04-22 | 拜尔公司 | 黄皮酰胺的制备方法 |
-
2015
- 2015-07-10 CN CN201510403792.1A patent/CN105017124A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN86107090A (zh) * | 1985-10-18 | 1987-04-22 | 拜尔公司 | 黄皮酰胺的制备方法 |
Non-Patent Citations (3)
Title |
---|
KRIMEN,ET AL.: "《Organic Reactions (New York)》", 31 December 1969 * |
LETICIA M. PARDO,ET AL.: "Application of the intramolecular PIFA-mediated amidation of alkynes to the synthesis of substituted indolizidinones", 《TETRAHEDRON》 * |
WOLFGANG HARTWIG,ET AL.: "Diastereoselective and Enantioselective Total Synthesis of the Hepatoprotective Agent Clausenamide", 《J. ORG. CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107056635A (zh) * | 2017-06-09 | 2017-08-18 | 广西师范大学 | 一种炔酰胺类化合物的合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101987843B (zh) | 常山酮氢溴酸盐及其类似物的合成方法 | |
TW201920097A (zh) | 製備化合物之製程 | |
CN106316889B (zh) | 依度沙班中间体的制备方法 | |
TW509672B (en) | Novel intermediate compounds and processes for the production of optical active octanoic acid derivatives | |
CN106365986A (zh) | 化合物及其制备方法和在合成布瓦西坦中的用途 | |
CN104072398B (zh) | 一种合成依折麦布的方法 | |
CN105017124A (zh) | 一种合成黄皮酰胺的新方法 | |
WO2018214676A1 (zh) | 布格呋喃原料药及其制备方法和应用 | |
CN111217791A (zh) | 依鲁司他中间体及其制备方法 | |
CN104710346B (zh) | 一种合成顺式‑1‑苄基‑3‑甲氨基‑4‑甲基‑哌啶的方法 | |
Ruan et al. | Detailed studies on the enantioselective synthesis and HPLC enantioseparation of N‐protected 3‐hydroxyglutarimides | |
CN107963976A (zh) | 一种苯乙醇胺类化合物中间体的制备方法 | |
CN108276299B (zh) | 达泊西汀有关物质的合成方法 | |
née Jones et al. | Studies on the scope and applications of the catalysed asymmetric addition of organolithium reagents to imines | |
CN104610067A (zh) | 一种金刚乙胺的合成方法 | |
CN103435462A (zh) | 一种茚幷菲酮衍生物及其制备方法 | |
CN104829571B (zh) | 草酸艾司西酞普兰相关物质及其制备方法 | |
CN112409235B (zh) | 一种手性4-卤代色氨酸衍生物及其合成方法 | |
Wang et al. | Practical asymmetric synthesis of a novel γ-secretase inhibitor | |
CN103664852B (zh) | 一种玫瑰醚的制备方法 | |
CN105330550A (zh) | 一种光学活性的1-环己基乙胺的制备方法 | |
CN108440376B (zh) | 一种盐酸罗匹尼罗的制备方法 | |
JP2005255660A (ja) | 多官能基を有するラクタム類とその製法 | |
CN113929575A (zh) | 一种(1r,2s)-二氢茉莉酮酸甲酯的制备方法 | |
CN106957318B (zh) | 稠合多环吲哚啉化合物、其制备方法、药物组合物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151104 |